

Investigating associations between a new measure of engagement-in-care and clinical outcomes in the UK Collaborative HIV Cohort (UK CHIC) Study

**Caroline Sabin¹, Alison Howarth¹, Sophie Jose¹, Teresa Hill¹,
Vanessa Apea², Fiona Burns¹**

¹UCL, London, UK; ²Barts Health NHS Trust



REACH




Background

- Several measures have been proposed for the assessment of engagement in-care (IC)
 - All gaps in care <6 months¹
 - ≥ 2 CD4/VL determinations, separated by 90 days, in any calendar year²
- Focus on loss-to-follow-up
- Often based on fixed clinic visit schedule
 - may not be responsive to changing status of patients or clinic policy

¹Yehia BR et al. *AIDS* 2012; 26: 1131-1139; ²Health Resources Services Administration, 2008

Background



REACH



Aim

To describe associations between a new dynamic measure of engagement IC and future mortality


REACH Study, Howarth A et al, poster P171



REACH

Development of a new measure to characterise retention in outpatient HIV care

Alison Howarth¹, Fiona Burns¹, Vanessa Apea², Sophie Jose¹, Teresa Hill¹, Caroline Sabin¹



¹ UCL Research Department of Infection and Population Health, London
² Barts Health NHS Trust, London



BACKGROUND

- Retention in outpatient HIV care is a key quality performance measure for specialist HIV services
- There is no gold standard measure of retention
- Standard measures are not responsive to changing health status of patients

AIM

The REACH project aims to explore, describe, and understand patterns of HIV outpatient attendance in people living with HIV, in order to develop cost effective interventions to optimise their engagement in care. As part of the REACH project, we sought to develop a measure of engagement in care that would incorporate time-updated data on the health status of patients.

METHODS

QUANTITATIVE DATA AND ANALYSIS

- Semi-structured, qualitative interviews with 8 HIV physicians, from 5 London HIV clinics
- Physicians described what prompted timing of patient's next scheduled appointment for last ten patients
- Content analysis of factors associated with time to next appointment

ALGORITHM DEVELOPMENT AND TESTING

- Clinical factors informed development of algorithm to define period that patients were engaged in / disengaged from HIV care
- Algorithm refined in discussion with REACH research team
- Algorithm applied to patients who made two or more visits to clinics in the UK Collaborative HIV Cohort (UK CHC) study
 - follow up censored at time of last recorded visit
 - CD4 count, viral load (VL), haemoglobin measure and/or ART start date used as surrogate markers of attendance
- Description of proportion of months where patients were engaged in care
- Comparison of proportion of months where patients were engaged in care by demographic characteristics

RESULTS

FACTORS INDICATED BY PHYSICIANS

- Patients routinely seen every 3-4 months
- Protocols around particular circumstances, such as new diagnoses and starting treatment
- Shorter intervals when, for example, patient had drop in CD4 count before starting treatment or virological breakthrough on treatment
- Routine visits extended to every 6 months if patients were well and stable - both on treatment and in social circumstances
- Importance of non HIV-specific factors in determining intervals between visits - such as comorbidities and psychosocial issues



Clinical factors available in routinely collected data and discussed in the physician interviews were incorporated into the algorithm, as summarised in Table 1. An example of how the algorithm applies to individual patients is shown in the CASE STUDY box.

Table 1: Algorithm measuring engagement in HIV care

Factors at clinic visit ¹	Next clinic visit expected within (months)
Within 1 month of diagnosis	2
AIDS diagnosis	2
Started treatment	2
Started new drug	2
Not on treatment	
CD4 < 500, CD4 drop > 100 ²	4
CD4 < 500, CD4 drop > 100, VL > 100,000 ²	6
CD4 < 500, CD4 drop > 100, VL > 100,000	4
CD4 350-500	4
CD4 < 350, any drop in CD4	2
CD4 < 350, no drop in CD4	4
On stable treatment	
VL > 200	2
VL < 51-200, does not appear to be blip	2
VL < 51-200, appears to be blip	4
VL < 50, CD4 > 200	4
VL < 50, CD4 > 200	6

¹ If a factor has not been indicated at the time of the clinic visit, the patient is assumed to be engaged in care for the shorter number of months associated with any of those factors. ² CD4 counting is optional. VL is optional.


CASE STUDY



ALGORITHM APPLIED TO UK CHC DATA

44,432 patients included in analysis. Overall, patients were engaged in care for 83.9% of 3,021,224 patient months. Similar to other analyses, engagement was associated with gender, ethnicity, mode of transmission and age (Figure 1).

Figure 1: Engagement in HIV care by background characteristics



CONCLUSIONS

While physicians highlighted the importance of clinical factors in determining time to next appointment, such factors are not included in standard measures of retention in outpatient HIV care. We have developed an algorithm to describe engagement in HIV care which incorporates a time-updated measure of patients' health and adds to the options available for measuring this key performance indicator.



Barts Health
NHS Trust

NHS
National Institute for
Health Research

The REACH project is funded by the National Institute for Health Research's HSAR Programme (project number 11000450). The views and opinions expressed here are those of the authors and do not necessarily reflect those of the HSAR Programme, NIHR, NHS or the Department of Health.

Methods

- **Care visit:** any visit associated with a CD4, viral load (VL), haemoglobin measurement, or ART start date
- Measurements within the same calendar month were assumed to relate to the same index visit
- **Patient eligibility:** >1 care visit between 1/1/2000-1/1/2013, and ≥ 1 month of follow-up after first care visit



REACH




Methods

Factors at clinic visit	Expected to return for care within (months)
Within 1 month of diagnosis	2
AIDS diagnosis	2
Started treatment	2
Started new drug	2
Not on treatment	
CD4>500, CD4 drop>100	4
CD4>500, CD4 drop<100, VL<100,000	6
CD4>500, CD4 drop<100, VL>100,000	4
CD4 350-500	4
CD4<350, any drop in CD4	2
CD4<350, no drop in CD4	4
On stable treatment	
VL>200	2
VL=51-200, does not appear to be blip	2
VL=51-200, appears to be blip	4
VL≤50, CD4<200	4
VL≤50, CD4>200	6



REACH

Methods



REACH



Statistical methods

- Cox models assessed association between mortality and:
 - a) cumulative proportion of months a person had been IC (%IC)
 - time-updated, lagged by 12 months
 - b) cumulative %IC prior to ART in those starting ART
 - restricted to those who had attended clinic for >1 year
- Follow-up censored at last visit or 1/1/2013
- Adjusted for age, year, sex, infection mode, ethnicity and receipt/type of ART
- Also adjusted for latest CD4/VL to investigate whether associations could be explained by poorer responses




Analysis 1: Characteristics of patients at ART start

All patients		
N		44,432
Gender, %	Male	72.2
	Female	27.8
Age (years)	Median (IQR)	36 (30, 42)
Exposure, %	MSM	50.5
	Heterosexual	39.1
	IDU	3.0
	Other/unknown	7.4
Ethnic group, %	White	53.3
	Black African	28.9
	Other	8.7
	Unknown	9.2
CD4 count (cells/mm ³)	Median (IQR)	355 (214, 520)



Analysis 1: RIC stratified by calendar year



REACH



Analysis 1: Association between %IC and mortality

	Death
Total number (%)	2279 (5.1%)
<i>Relative hazard [95% CI] /10% higher IC</i>	
No adjustment	0.91 [0.88, 0.95]

*Age, CD4 and year of entry, sex, mode of infection, ethnicity



REACH



Analysis 1: Association between %IC and mortality

	Death
Total number (%)	2279 (5.1%)
<i>Relative hazard [95% CI] /10% higher IC</i>	
No adjustment	0.91 [0.88, 0.95]
Adjustment for fixed covariates and ART*	0.90 [0.87, 0.93]

*Age, CD4 and year of entry, sex, mode of infection, ethnicity



REACH



Analysis 1: Association between %IC and mortality

	Death
Total number (%)	2279 (5.1%)
<i>Relative hazard [95% CI] /10% higher IC</i>	
No adjustment	0.91 [0.88, 0.95]
Adjustment for fixed covariates and ART*	0.90 [0.87, 0.93]
CD4 count changes over follow-up	1.00 [0.96, 1.04]

*Age, CD4 and year of entry, sex, mode of infection, ethnicity



REACH



Analysis 2: Characteristics of patients at ART start

		All patients	At ART
N		44,432	8,730
Gender, %	Male	72.2	78.2
	Female	27.8	21.8
Age (years)	Median (IQR)	36 (30, 42)	37 (32, 43)
Exposure, %	MSM	50.5	62.3
	Heterosexual	39.1	31.1
	IDU	3.0	2.9
	Other/unknown	7.4	3.7
Ethnic group, %	White	53.3	63.4
	Black African	28.9	20.9
	Other	8.7	8.9
	Unknown	9.2	6.8
CD4 count (cells/mm ³)	Median (IQR)	355 (214, 520)	280 (202, 368)



REACH



Analysis 2: Characteristics of patients at ART start, stratified by %IC prior to ART

% months IC prior to ART	% of group	Male	MSM	White	CD4 (cells/mm ³)	Regimen	
	%	%	%	%	Median	PI	NNRTI
<50%	14.7	14.7	46.2	53.5	250	32.1	60.8
50-70%	14.2	14.2	59.5	60.9	259	25.3	66.4
70-80%	11.6	11.6	62.8	62.1	280	25.5	67.5
80-90%	18.2	18.2	65.6	64.9	283	26.2	67.1
90-99%	24.0	24.0	66.4	65.6	290	23.0	68.6
100%	17.3	17.3	68.6	70.3	299	21.4	70.0



REACH



Analysis 2: Characteristics of patients at ART start, stratified by %IC prior to ART

% months IC prior to ART	% of group	Male	MSM	White	CD4 (cells/mm ³)	Regimen	
	%	%	%	%	Median	PI	NNRTI
<50%	14.7	73.1	46.2	53.5	250	32.1	60.8
50-70%	14.2	76.0	59.5	60.9	259	25.3	66.4
70-80%	11.6	77.7	62.8	62.1	280	25.5	67.5
80-90%	18.2	80.1	65.6	64.9	283	26.2	67.1
90-99%	24.0	79.3	66.4	65.6	290	23.0	68.6
100%	17.3	81.0	68.6	70.3	299	21.4	70.0



REACH



Analysis 2: Characteristics of patients at ART start, stratified by %IC prior to ART

% months IC prior to ART	% of group	Male	MSM	White	CD4 (cells/mm ³)	Regimen	
	%	%	%	%	Median	PI	NNRTI
<50%	14.7	73.1	46.2	53.5	250	32.1	60.8
50-70%	14.2	76.0	59.5	60.9	259	25.3	66.4
70-80%	11.6	77.7	62.8	62.1	280	25.5	67.5
80-90%	18.2	80.1	65.6	64.9	283	26.2	67.1
90-99%	24.0	79.3	66.4	65.6	290	23.0	68.6
100%	17.3	81.0	68.6	70.3	299	21.4	70.0



REACH



Analysis 2: Characteristics of patients at ART start, stratified by %IC prior to ART

% months IC prior to ART	% of group	Male	MSM	White	CD4 (cells/mm ³)	Regimen	
	%	%	%	%	Median	PI	NNRTI
<50%	14.7	73.1	46.2	53.5	250	32.1	60.8
50-70%	14.2	76.0	59.5	60.9	259	25.3	66.4
70-80%	11.6	77.7	62.8	62.1	280	25.5	67.5
80-90%	18.2	80.1	65.6	64.9	283	26.2	67.1
90-99%	24.0	79.3	66.4	65.6	290	23.0	68.6
100%	17.3	81.0	68.6	70.3	299	21.4	70.0



Analysis 2: Characteristics of patients at ART start, stratified by %IC prior to ART

% months IC prior to ART	% of group	Male	MSM	White	CD4 (cells/mm ³)	Regimen	
	%	%	%	%	Median	PI	NNRTI
<50%	14.7	73.1	46.2	53.5	250	32.1	60.8
50-70%	14.2	76.0	59.5	60.9	259	25.3	66.4
70-80%	11.6	77.7	62.8	62.1	280	25.5	67.5
80-90%	18.2	80.1	65.6	64.9	283	26.2	67.1
90-99%	24.0	79.3	66.4	65.6	290	23.0	68.6
100%	17.3	81.0	68.6	70.3	299	21.4	70.0



REACH



Analysis 2: Association between %IC pre-ART and mortality post-ART

	Death
Total number (%)	237 (2.7%)
<i>Relative hazard [95% CI] /10% higher IC</i>	
No adjustment	0.29 [0.18, 0.47]
Adjustment for fixed covariates*,	0.36 [0.21, 0.61]
+ Latest CD4 count and VL	0.74 [0.42, 1.30]

*Age, sex, mode of infection, ethnicity, calendar year, pre-ART CD4 and VL



REACH



Summary and discussion

- Higher engagement in-care is associated with improved clinical outcomes, at least one year into the future as well as among those on ART
- Largely explained by poorer CD4 profiles in those with sub-optimal engagement in-care
- Algorithm provides flexible approach to measuring engagement that can be adapted to the changing status of the patient and to local clinic policies

Limitations and other issues

- Dates of laboratory markers and ART start dates used as surrogates for clinic visits
 - Do we miss visits without associated laboratory tests?
 - How to deal with repeated measurements within same month?
- Algorithm does not capture additional information that might modify a clinician's decision about timing of next visit (e.g. psycho-social factors)
 - May over-estimate %IC as a result



REACH



UK CHIC: Acknowledgements

Research Department of Infection and Population Health, UCL Medical School: C Sabin, T Hill, A Phillips, S Jose, S Huntington, A Thornton

Medical Research Council Clinical Trials Unit (MRC CTU): D Dunn, A Glabay

Brighton and Sussex University Hospitals NHS Trust : M Fisher, D Churchill, N Perry, S Tilbury

Chelsea and Westminster NHS Trust: B Gazzard, M Nelson, M Waxman, D Asboe, S Mandalia

Kings College London School of Medicine, GKT Hospitals: F Post, H Korat, C Taylor, Z Gleisner, F Ibrahim, L Campbell

Mortimer Market Centre, UCL Medical School: R Gilson, N Brima, I Williams

Royal Free NHS Trust/UCL Medical School: M Johnson, M Youle, F Lampe, C Smith, A Phillips, R Tsintas, C Chaloner, S Hutchinson

Imperial College Healthcare NHS Trust: J Walsh, N Mackie, A Winston, J Weber, F Ramzan

Barts and the London NHS Trust: C Orkin, J Lynch, J Hand, C de Souza

Homerton University Hospital NHS Trust: J Anderson, S Munshi, D Awosika

The Lothian University Hospital NHS Trust: C Leen, A Wilson

North Middlesex University Hospital NHS Trust: A Schwenk, J Ainsworth, C Wood, S Miller

Health Protection Agency Centre for Infections: V Delpach

North Bristol NHS Trust: M Gompels, S Allan

University of Leicester NHS Trust: A Palfreeman, A Moore, L Fox

South Tees Hospitals NHS Foundation Trust: D Chadwick, K Baillie

Woolwich NHS Trust: S Kegg, P Main

Coventry NHS Trust: S Allan

St. George's NHS Trust: P Hay, M Dhillon

York: F Martin, S Douglas

The Royal Wolverhampton Hospitals NHS Trust: A Tariq, H Spencer, R Jones

Chertsey, Ashford and St Peter's Hospitals NHS Foundation Trust: J Pritchard, S Cumming, C Atkinson

UK CHIC is funded by the UK Medical Research Council



Exploring patterns of Retention and Engagement Across specialised Care services for HIV

REACH Management Team

Fiona Burns (PI), Caroline Sabin (co-PI), Alison Howarth, Cath Mercer (**Research Department of Infection and Population Health, UCL**); Vanessa Apea (**Barts Health NHS Trust**); Valerie Delpech (**Public Health England**); Amanda Evans (**Royal Free London NHS Foundation Trust**); Susan Michie (**Division of Psychology, UCL**); Steve Morris (**Department of Applied Health Research, UCL**); Memory Sachikonye (**UK Community Advisory Board**)

REACH Study Steering Committee

Paul Clift (**King's College Hospital NHS Foundation Trust**); Paul Flowers (**Glasgow Caledonian University**); Jonathan Stern (**University of Bristol**); Ann Sullivan (**Chelsea & Westminster Hospital NHS Foundation Trust**)

REACH Advisory Group and Local PIs

Jane Anderson (**Homerton University Hospital NHS Foundation Trust**); Tristan Barber (**Chelsea & Westminster Hospital NHS Foundation Trust**); Simon Edwards (**Central and North West London NHS foundation Trust**); Julie Fox (**Guy's and St Thomas' NHS Foundation Trust**); Ana Milinkovic (**Research Department of Infection and Population Health, UCL**); Rebecca O'Connell (**Barts Health NHS Trust**); Iain Reeves (**Homerton University Hospital NHS Foundation Trust**); Leena Sathia (**Royal Free London NHS Foundation Trust**); Sophie Strachan (**Positively UK**)



REACH



**National Institute for
Health Research**